Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this study, researchers observed that EGFR deficiency in the epidermis affects gene expression related to cell differentiation and structure, highlighting spatial and temporal roles of EGFR during skin and hair follicle development.

In this study, researchers reviewed cases of EGFR inhibitor-induced folliculitis decalvans and reported the first known occurrences associated with afatinib in three female NSCLC patients, highlighting the importance of early diagnosis and management to improve patient quality of life.

This study suggests that cutaneous lymphadenoma is a distinct benign lymphoepithelial tumor characterized by androgen receptor expression, hair follicle stem cell markers, and common EGFR gene mutations.

This article discusses the cutaneous side effects of erlotinib, an EGFR inhibitor, in a patient with non-small cell lung cancer, reporting nonscarring alopecia and indicative scalp biopsy findings.

This article reviews common skin reactions associated with epidermal growth factor receptor inhibitors and reports no new clinical findings, emphasizing the need for understanding nursing care and oncodermatology.

This study suggests that erlotinib exacerbates inflammation in a mouse model of skin disease and that IL-1 inhibition could mitigate skin-related side effects of EGFR inhibitors.

This article reviews skin toxicity classifications and management in patients undergoing molecularly targeted therapy, noting significant dermatotropic side effects associated with Epidermal Growth Factor Receptor Inhibitors.

This article discusses the clinical manifestations and management strategies of skin side effects from epidermal growth factor receptor inhibitors, but reports no new clinical findings.

In this reported case, a 50-year-old man developed an acneiform rash, a common skin side effect of EGFR inhibitor therapy, after starting lapatinib for breast cancer; treatment with doxycycline and hydrocortisone cream led to significant improvement within one week.

This article presents a rare case of cicatricial alopecia in a 59-year-old woman after using the epidermal growth factor receptor inhibitor gefitinib.

This study found that continuous expression of epidermal growth factor in transgenic mice prevented hair follicles from entering the catagen phase, implicating EGF as a crucial regulator in hair cycle progression.

In a transgenic mouse model, this study found that overexpression of keratin 16 in skin keratinocytes led to hyperkeratosis and increased EGF receptor signaling, altering skin cell behavior and structure.

This review discusses the skin side effects associated with targeted cancer therapies and reports no new clinical results; it emphasizes the need for empirical management based on expert opinion.

This study found that EGFR and MEK inhibitors may induce acneiform skin toxicities by interacting with the skin bacterium Cutibacterium acnes to increase IL-36γ and IL-8 production in keratinocytes.

This study found that in mice lacking EGFR, elevated Wnt signaling disrupts hair follicle development by affecting cell proliferation and differentiation, revealing a critical role for EGFR in regulating these processes.

This case report describes a 57-year-old Japanese female who developed scarring alopecia linked to gefitinib, an EGFR inhibitor, with improvement in hair loss after reducing the drug dosage.

This article reviews the cutaneous reactions and characteristic skin changes associated with chemotherapy, radiation therapy, and new targeted cancer treatments, reporting no new clinical results.

This article discusses common skin side effects of EGFR inhibitors like cetuximab, noting their management remains based on clinical experience without strict therapy protocols, but provides no new clinical findings.

This study found that treatment with EGFR inhibitors or mitogen-activated kinase inhibitors may compromise the immune privilege of human scalp hair follicles, suggesting new directions for managing drug-induced folliculitis.

In this study, a combined therapy of nicotinamide and green tea polyphenols was reported to improve EGFR inhibitor-related skin toxicity and patient quality of life, suggesting it merits further investigation.

This study suggests that Isaria cicadae Miquel rice fermentation extract may enhance regenerative wound healing of hair follicles in mouse skin through the Hippo pathway mechanism.

This article discusses the range of skin-related side effects caused by chemotherapy and radiotherapy, including novel patterns emerging with targeted therapies, but does not report new clinical results.

This study found that epidermal growth factor receptor inhibitors used in cancer treatment induce a distinct inflammatory response in hair follicles, marked by immune privilege collapse and upregulation of inflammatory pathways.

This study found that epidermal growth factor receptor and mitogen activated protein kinase inhibitors down-regulate PD-L1 expression in human hair follicles, which may contribute to sterile folliculitis in treated patients.

This chapter reviews the skin side effects associated with targeted cancer therapies and emphasizes the importance of collaboration between oncologists and dermatologists without reporting new results.

This symposium review highlights past, present, and future developments in skin research, celebrating the work of Prof. Johanna Brandner and Dr. Peter Arne Gerber, without reporting new clinical results.

This study observed that trichoscopic changes associated with EGFRI treatment include pili torti and asymmetric hyperpigmented fusiform widening, along with dermoscopic skin manifestations such as scale and branching vessels.

This review discusses the common dermatologic side effects of epidermal growth factor receptor inhibitors and provides practical guidance for recognizing and managing these effects; it reports no new clinical results.

This study reports two cases of erlotinib-induced erosive pustular dermatosis of the scalp in patients with non-small cell lung cancer, emphasizing the need for dermatological monitoring during EGFR inhibitor therapy.

This review discusses the presentation and management of skin toxicity from epidermal growth factor inhibitors, highlighting a correlation between cutaneous adverse effects and tumor response, but reports no new clinical results.